Vol 55, No 6 (2024)
Guidelines / Expert consensus
Published online: 2024-12-31
Mutations of variable parts of immunoglobulin heavy chains (IGHV) — assay methodology and recommendations on how to report results
DOI: 10.5603/ahp.103244
Acta Haematol Pol 2024;55(6):306-319.
Abstract
Currently, the evaluation of mutational status of variable region of immunoglobulin heavy chain gene (IGHV) makes
up one of the key prognostic and predictive tests in patients with chronic lymphocytic leukaemia (CLL), performed
before the initiation of the first line therapy. This publication presents the first edition of the Polish recommendations
of the Molecular Haematology Section of the Polish Society of Human Genetics (PTGC) concerning the methodology of
IGHV mutation status determination and the principles of reporting the results based on the recognised international
standards.
Keywords: chronic lymphocytic leukaemia (CLL)IGHV mutationrecommendationsreporting
References
- Wierda WG, Brown J, Abramson JS, et al. NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. J Natl Compr Canc Netw. 2022; 20(6): 622–634.
- Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7): 1720–1748.
- Białopiorowicz E, Juszczyński P. Molekularna patogeneza przewlekłej białaczki limfocytowej. Hematologia. 2017; 7(4): 273–286.
- Wendtner CM. CLL: deep dive for residual cells by NGS matters. Blood. 2019; 134(22): 1883–1884.
- Obwieszczenie Ministra Zdrowia z dnia 18 marca 2024 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych na 1 kwietnia 2024 r. PL-17475 (Załącznik B. ; 79.
- Hus I, Giannopoulos K, Jamroziak K, et al. Diagnostic and therapeutic recommendations of the Polish Society of Haematologists and Transfusiologists, and Polish Adult Leukemia Group-CLL for chronic lymphocytic leukemia in 2023. Acta Haematologica Polonica. 2023; 54(6): 342–371.
- Rozporządzenie Ministra Zdrowia w sprawie standardów jakości dla medycznych laboratoriów diagnostycznych i mikrobiologicznych z dnia 23 marca 2006 r. Dz.U. z 2019 r. . 1923 i 2065 oraz z 2020 r. poz. ; 464: i.
- Agathangelidis A, Chatzidimitriou A, Chatzikonstantinou T, et al. ERIC, the European Research Initiative on CLL. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL. Leukemia. 2022; 36(8): 1961–1968.
- Ghia P, Stamatopoulos K, Belessi C, et al. European Research Initiative on CLL. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia. 2007; 21(1): 1–3.
- Rosenquist R, Ghia P, Hadzidimitriou A, et al. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations. Leukemia. 2017; 31(7): 1477–1481.
- Stamatopoulos B, Timbs A, Bruce D, et al. Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia. Leukemia. 2017; 31(4): 837–845.
- Hengeveld PJ, Levin MD, Kolijn PM, et al. Reading the B-cell receptor immunome in chronic lymphocytic leukemia: revelations and applications. Exp Hematol. 2021; 93: 14–24.
- Agathangelidis A, Chatzidimitriou A, Gemenetzi K, et al. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. Blood. 2021; 137(10): 1365–1376.
- Chatzikonstantinou T, Agathangelidis A, Chatzidimitriou A, et al. ERIC, the European Research Initiative on CLL. Updates of the ERIC recommendations on how to report the results from immunoglobulin heavy variable gene analysis in chronic lymphocytic leukemia. Leukemia. 2024; 38(3): 679–680.
- Al-Sawaf O, Zhang C, Jin HY, et al. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nat Commun. 2023; 14(1): 2147.
- Baliakas P, Agathangelidis A, Hadzidimitriou A, et al. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. Blood. 2015; 125(5): 856–859.
- Jaramillo S, Agathangelidis A, Schneider C, et al. Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). Haematologica. 2020; 105(11): 2598–2607.
- Rossi D, Spina V, Cerri M, et al. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res. 2009; 15(13): 4415–4422.
- Ustawa z dnia 15 września 2022 r. o medycynie laboratoryjnej. Dz.U. 2022 poz. ; 2280.
- Rozporządzenie Ministra Zdrowia z dnia 6 kwietnia 2020 r. w sprawie rodzajów, zakresu i wzorów dokumentacji medycznej oraz sposobu jej przetwarzania. Dz.U. 2024 poz. ; 666.